Cure My Disease

Don't miss your cure!

 Log in / Sign up

A cheap blood test could flag hidden liver fat in metabolic syndrome

NCT ID NCT07780253

Diagnosis Sponsor: Assiut University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 21, 2026 · Last updated Aug 21, 2026

Summary

This study tests whether a simple calculation from a standard blood test—the creatinine-to-body weight ratio—can predict fatty liver disease in people with metabolic syndrome. Metabolic syndrome is a cluster of conditions like obesity, high blood pressure, and high blood sugar that raises the risk of liver fat buildup. The researchers will measure this ratio in 96 adults with metabolic syndrome and see how well it matches liver fat levels, aiming to find an inexpensive, easy screening tool.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
No drug or treatment is being tested. The study evaluates a simple blood test ratio (creatinine-to-body weight) as a screening tool for fatty liver.
What this could lead to
If this simple ratio works, it could offer a cheap, widely available way to spot fatty liver early in people with metabolic syndrome, helping prevent serious liver damage.
What could go wrong
This is a small, single-center study, and the ratio may not prove accurate enough across different populations. It is a screening tool, not a treatment, and needs validation before any clinical use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 96 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with metabolic syndrome

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged ≥18 years. • Patients fulfilling criteria of metabolic syndrome Metabolic syndrome will be diagnosed according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criteria. Presence of at least three of the following: 1. Waist circumference: * Men\>102 cm * Women\>88 cm 2. Triglycerides ≥150 mg/dL or treatment for hypertriglyceridemia. 3. HDL cholesterol: * Men\<40 mg/dL * Women\<50 mg/dL 4. Blood pressure ≥130/85 mmHg or current antihypertensive treatment. 5. Fasting blood glucose ≥100 mg/dL or treatment for diabetes mellitus. • Patients willing to participate and provide informed consent. Exclusion Criteria: * Chronic liver disease other than MASLD. * Viral hepatitis B or C. * Significant alcohol intake. * Hepatotoxic drug use. * Chronic kidney disease stage 4 or 5. * Acute kidney injury. * Malignancy. * Pregnancy. * Active infection or inflammatory disease

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metabolic syndrome (METS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

abdominal obesity-metabolic syndrome metabolic syndrome X

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metabolic syndrome (METS)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.